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ABSTRACT 
Germline loss- and gain-of-function mutations 
of G-protein alpha-11 (Gα11), which couples the 
calcium-sensing receptor (CaSR) to 
intracellular calcium (Ca2+i) signaling, lead to 
familial hypocalciuric hypercalcemia type 2 
(FHH2) and autosomal dominant hypocalcemia 
type 2 (ADH2), respectively, whereas somatic 
Gα11 mutations mediate uveal melanoma 
development by constitutively upregulating 
MAPK signaling. Cinacalcet and NPS-2143 are 
allosteric CaSR activators and inactivators, 
respectively, that ameliorate signaling 
disturbances associated with CaSR mutations, 
but their potential to modulate abnormalities of 
the downstream Gα11 protein is unknown. This 
study investigated whether cinacalcet and NPS-
2143 may rectify Ca2+i alterations associated 
with FHH2- and ADH2-causing Gα11 mutations, 
and evaluated the influence of germline gain-of-
function Gα11 mutations on MAPK signaling by 
measuring ERK phosphorylation, and assessed 
the effect of NPS-2143 on a uveal melanoma 
Gα11 mutant. WT and mutant Gα11 proteins 
causing FHH2, ADH2 or uveal melanoma were 
transfected in CaSR-expressing HEK293 cells, 
and Ca2+i and ERK1/2 phosphorylation 
responses measured by flow-cytometry and 
Alphascreen immunoassay following exposure 
to extracellular Ca2+ (Ca2+o) and allosteric 
modulators. Cinacalcet and NPS-2143 rectified 
the Ca2+i responses of FHH2- and ADH2-
associated Gα11 loss- and gain-of-function 
mutations, respectively. ADH2-causing Gα11 
mutations were demonstrated not to be 
constitutively activating and induced ERK 
phosphorylation following Ca2+o stimulation 
only. The increased ERK phosphorylation 
associated with ADH2 and uveal melanoma 
mutants was rectified by NPS-2143. These 
findings demonstrate that CaSR-targeted 
compounds can rectify signaling disturbances 
caused by germline and somatic Gα11 
mutations, which respectively lead to calcium 
disorders and tumorigenesis; and that ADH2-
causing Gα11 mutations induce non-constitutive 
alterations in MAPK signaling. 
 
Guanine nucleotide-binding protein (G-protein) 
alpha-11 (Gα11) is a major intracellular signaling 
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partner of the cell-surface G-protein-coupled 
calcium (Ca2+)-sensing receptor (CaSR), which 
plays a pivotal role in the parathyroid and renal 
regulation of extracellular calcium (Ca2+o) 
concentrations (1,2). Gα11 belongs to the Gq/11 class 
of G-proteins that enhance phospholipase C 
activity (3), thereby leading to an accumulation of 
inositol 1,4,5-trisphosphate and rapid increase in 
intracellular Ca2+ (Ca2+i) concentrations (2,4). 
These signal transduction events allow the CaSR 
to respond to small fluctuations in the prevailing 
Ca2+o concentration ([Ca2+]o) by inducing 
alterations in parathyroid hormone (PTH) 
secretion and urinary Ca2+ excretion (5).  
The identification of germline 
heterozygous loss- and gain-of-function mutations 
of Gα11, which is encoded by the GNA11 gene on 
chromosome 19p13.3, that lead to forms of 
familial hypocalciuric hypercalcemia (FHH) or 
autosomal dominant hypocalcemia (ADH), 
respectively, has demonstrated the importance of 
this G-protein subunit in Ca2+o homeostasis 
(1,6,7). FHH is a genetically heterogeneous 
disorder that is inherited as an autosomal dominant 
condition, which is characterised by lifelong 
elevations of serum Ca2+ concentrations in 
association with normal or mildly raised serum 
PTH levels and low urinary Ca2+ excretion (8). 
FHH is considered to represent a benign disorder, 
however some patients may develop symptomatic 
hypercalcemia, pancreatitis or chondrocalcinosis 
(8). FHH type 1 (FHH1, OMIM #145980) is 
caused by loss-of-function mutations of the CASR 
gene (9), and FHH type 2 (FHH2, OMIM 
#145981) is caused by loss-of-function Gα11 
mutations, which comprise a Leu135Gln missense 
substitution and in-frame isoleucine deletion at 
codon 199 or 200 (Ile199/200del) that impair 
CaSR signal transduction and were identified in 
two unrelated probands and families (1). ADH is 
also genetically heterogeneous and caused by 
germline gain-of-function mutations of the CASR 
and GNA11 genes, which lead to ADH types 1 
(ADH1, OMIM #601198) and 2 (ADH2, OMIM 
#615361), respectively (1,6-10). Approximately 
50% of ADH patients develop hypocalcemic 
symptoms such as paraesthesia, carpo-pedal 
spasms and seizures, and >35% of patients harbor 
ectopic calcifications within the kidneys or basal 
ganglia (1,6,7,10). In contrast to germline gain-of-
function Gα11 mutations, which affect Ca2+o 
homeostasis, somatic gain-of-function Gα11 
mutations have been reported to lead to uveal 
melanoma, which is a primary intraocular tumor, 
by inducing constitutive up-regulation of 
proliferative signaling involving ERK, which is a 
component of the MAPK signaling pathway (11).  
Compounds that selectively bind to the 
CaSR and allosterically modulate the function of 
this family C G-protein-coupled-receptor (GPCR) 
represent a potential targeted therapy for patients 
with symptomatic forms of FHH and ADH. 
Indeed, cinacalcet, which is a licenced CaSR 
positive allosteric modulator, has been used 
effectively in FHH1 patients to manage 
symptomatic hypercalcemia and recurrent 
pancreatitis (12,13). Furthermore, negative 
allosteric CaSR modulators, known as calcilytics, 
have been demonstrated to ameliorate 
hypocalcemia in mouse models of ADH1 (14,15). 
The objective of this study was to undertake in 
vitro studies to determine whether allosteric 
modulators targeted to the CaSR may also rectify 
the loss- and gain-of-function associated with 
FHH2- and ADH2-causing germline Gα11 
mutations, respectively, and the upregulation of 
ERK phosphorylation caused by a uveal 
melanoma-associated somatic Gα11 mutation. In 
addition, this study evaluated whether germline 
ADH2-causing gain-of-function Gα11 mutations 
may constitutively activate MAPK signaling and 
thus pose a risk for the development of uveal 
melanomas. 
 
EXPERIMENTAL PROCEDURES 
Cell culture and transfection - Functional 
studies of mutant Gα11 proteins were performed in 
HEK293 cells that stably expressed the CaSR 
(HEK-CaSR) (1,16,17). HEK293 cells 
endogenously express Gα11, and co-expression of 
mutant Gα11 proteins approximately represented 
the heterozygous state in FHH2 and ADH2 
patients (1). The HEK-CaSR cell line was cultured 
in high-glucose DMEM (Invitrogen) supplemented 
with 10% fetal bovine serum (FBS) and 1% 
geneticin, as described (1,16,17). A high level of 
CaSR expression in these cells was confirmed by 
Western blot analysis using a mouse monoclonal 
antibody to human CaSR (ADD; Abcam, ab19347, 
1:1,000) (1,16). WT and mutant GNA11-pBI-
CMV2 constructs were transiently transfected into 
HEK-CaSR cells using Lipofectamine 2000 
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(1,16,17). The bidirectional pBI-CMV2 cloning 
vector was used as it facilitated the co-expression 
of Gα11 and GFP (1,16,18). Expression of WT and 
mutant Gα11 proteins were determined by Western 
blot analysis using a mouse monoclonal anti-Gα11 
antibody (SantaCruz, sc-390382, 1:750), and the 
membrane was re-probed with a polyclonal rabbit 
anti-α-tubulin antibody (Abcam, ab15246, 1:1000) 
as a loading control. Successful transfection was 
also confirmed by visualising GFP fluorescence 
using an Eclipse E400 fluorescence microscope 
with a Y-FL Epifluorescence attachment and a 
triband 4,6-diamidino-2-phenylindole-FITC-
Rhodamine filter, and images captured using a 
DXM1200C digital camera and NIS-Elements 
software (Nikon) (1,16,17). 
Studies involving siRNA knockdown of 
endogenous Gα11 were undertaken in HEK293 
cells that stably expressed WT or mutant Gα11 
proteins (HEK-Gα11). The HEK-Gα11 cells were 
generated using HEK293 T-Rex-Flp-in stable cell-
lines (Life Technologies), as reported (19). WT 
and mutant GNA11 constructs were cloned into the 
pcDNA5/FLP recombination target (FRT) 
expression vector (Life Technologies), and silent 
mutations introduced to render the constructs 
resistant to GNA11-targeted siRNA, thereby 
allowing investigation of the mutant Gα11 protein 
in the absence of endogenous WT Gα11. GNA11 
constructs were transiently transfected into T-Rex-
Flp-in cells, and those cells expressing the Gα11 
protein selected by culturing cells in media 
containing Hygromycin (Gibco). The presence of 
the Gα11 protein, and its resistance to siRNA was 
confirmed by Western blot analysis. Forty-eight 
hours prior to measuring Ca2+i responses, HEK-
Gα11 cells were transiently transfected with the 
reported pEGFP-CaSR construct (9) and three 
different commercially available GNA11-targeted 
siRNA constructs (Trilencer-27 siRNA kit, catalog 
number SR301839, Origene) or a commercially 
available scrambled siRNA (Trilencer-27 
universal scrambled negative control siRNA 
duplex, catalog number SR30004, Origene), and 
successful transfection confirmed by fluorescence 
microscopy, as described for pBI-CMV2-
expressing HEK-CaSR cells (1,16,17).  
Measurement of Ca2+i responses - The 
effect of allosteric CaSR modulators on HEK-
CaSR cells expressing WT or mutant Gα11 
proteins was assessed by a flow cytometry-based 
Ca2+i assay, as reported (1,16,17). In brief, 48 
hours after transfection, the cells were harvested, 
washed in Ca2+- and magnesium (Mg2+)-free 
Hank's balanced salt solution (HBSS) (Invitrogen) 
and loaded with 1 µg/ml indo-1-
acetoxymethylester (Indo-1-AM) (Molecular 
Probes) for 1 hour at 37 °C (1,16,17). Transfected 
HEK-CaSR cells were incubated with either a 
20% aqueous solution of 2-hydroxypropyl-β-
cyclodextrin (Sigma) (vehicle), or positive or 
negative CaSR allosteric modulators, known as 
cinacalcet or NPS-2143, respectively, at 
concentrations ranging from 10-40 nM for 1 hour 
(15). Flow cytometry was performed with a 
Beckman Coulter MoFlo XDP equipped with 
JDSUY Xcyte UV Laser and a Coherent Sapphire 
488 Laser	 using a 550LP dichroic mirror and 
580/30 bandpass filter (17). Single cells were 
isolated and stimulated by sequentially adding 
Ca2+ to the Ca2+- and Mg2+-free HBSS to increase 
the [Ca2+]o in a stepwise manner from 0-15 mM. 
The range of [Ca2+]o used to activate CaSR 
signaling in HEK293 cells was not representative 
of physiological levels of serum ionized calcium, 
which are homeostatically maintained between 
1.1-1.3 mM (20), but use of these Ca2+o 
concentrations in vitro allowed a comprehensive 
assessment of CaSR signaling responses, which 
included threshold responses (1-1.5 mM Ca2+o), 
half-maximal (EC50) responses (2-4 mM Ca2+o) 
and near-maximal responses (>10 mM), as 
reported (21). The baseline fluorescence ratio was 
measured for 2 min, the fluorescence ratio 
compared to the time was recorded and data were 
collected for 2 min at each [Ca2+]o, as described 
(1,16,17). Cytomation Summit software was used 
to determine the peak mean fluorescence ratio of 
the transient response after each individual 
stimulus, which was expressed as a percentage 
normalized response (1,16,17). Concentration-
response curves were generated using a 4-
parameter non-linear regression curve-fit model  
(GraphPad Prism) to calculate the half-maximal 
(EC50) and area under the curve (AUC) mean ± 
SEM responses for each separate experiment (17). 
Measurement of ERK phosphorylation - 
HEK-CaSR cells, transfected with WT or mutant 
Gα11 proteins for 24 hours, were seeded in 48-well 
plates and cultured overnight in high glucose 
DMEM containing 10% FBS, prior to being 
incubated for 4 hours with serum-free DMEM 
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containing 0.5 mM Ca2+, 25 mM HEPES buffer 
with or without cinacalcet or NPS-2143 at 10-500 
nM concentrations. Cells were stimulated for 4 
min with pre-warmed serum-free DMEM that 
contained Ca2+ concentrations ranging from 0.5-10 
mM, as reported (22), and lysed in Surefire lysis 
buffer. Alphascreen Surefire ERK phosphorylation 
assays were performed on whole cell lysates, as 
reported (23), and the fluorescence signal 
measured using a PHERAStar FS microplate 
reader (BMG Labtech) (23). ERK phosphorylation 
responses measured at each [Ca2+]o were 
normalized to the mean responses of WT 
expressing cells and expressed as a fold-change of 
responses obtained at basal (0.5 mM) [Ca2+]o. 
Statistical analysis - The Ca2+i and ERK 
phosphorylation responses of cells expressing WT 
or mutant Gα11 proteins were compared from a 
minimum of four experiments using the F-test and 
Mann-Whitney U test, respectively (1). All 
analyses were undertaken using GraphPad Prism 
(GraphPad), and are presented as mean ± SEM. A 
value of p<0.05 was considered significant for all 
analyses.  
 
RESULTS 
Effect of cinacalcet on the Ca2+i responses 
of FHH2-associated Gα11 mutations - The FHH2-
associated Leu135Gln and Ile199/200del Gα11 
mutations have been reported to impair the 
sensitivity of CaSR-expressing cells to Ca2+o (1), 
and we hypothesized that cinacalcet-mediated 
allosteric activation of the CaSR would ameliorate 
the loss-of-function associated with germline 
mutations of Gα11, thereby rectifying the signal 
transduction abnormalities in cells expressing 
these FHH2-associated mutant Gα11 proteins. To 
investigate this hypothesis, WT or mutant GNA11-
pBI-CMV2 constructs were transiently transfected 
in HEK-CaSR cells and the effect of cinacalcet on 
the responses of Ca2+i concentrations ([Ca2+]i) to 
alterations in [Ca2+]o was assessed. Expression of 
the CaSR and Gα11 was confirmed by fluorescence 
microscopy and/or Western blot analysis of whole-
cell lysates (Fig. 1A and B). CaSR expression, 
which was normalised by comparison to α-tubulin 
expression, did not differ between cells transfected 
with WT or FHH2-associated mutant GNA11-pBI-
CMV2 vectors when compared to cells transfected 
with empty vector, whereas the expression of Gα11 
was greater in cells transfected with WT or mutant 
constructs (Fig. 1B). HEK-CaSR cells transiently 
transfected with WT or mutant Gα11 proteins were 
exposed to varying [Ca2+]o, and measurement of 
Ca2+i responses by flow cytometry revealed the 
FHH2-associated Gln135 and del199/200 Gα11 
mutants to result in a rightward shift of the 
concentration-response curves (Fig. 1C) with a 
significant reduction in AUC values and  increases 
in EC50 values (Gln135 = 3.54 ± 0.07 mM, 
del199/200  = 3.49 ± 0.04 mM) compared to WT 
Gα11 (2.67 ± 0.03 mM; p<0.0001) (Fig. 1D-E), as 
reported (1). A dose-titration of cinacalcet in cells 
expressing the Gln135 Gα11 mutant revealed this 
calcimimetic to act in a dose-dependent manner, 
with 10 and 20 nM drug concentrations 
significantly (p<0.0001) reducing the Gln135 
mutant EC50 values to 2.75 ± 0.03 and 2.61 ± 0.09 
mM, respectively (Fig. 1E). Indeed, 10 nM of 
cinacalcet induced a leftward shift of the mutant 
concentration-response curve, so that this was 
indistinguishable from that of WT-expressing cells 
(Fig. 1F). The addition of 10 and 20 nM cinacalcet 
lowered the EC50 values of cells expressing the 
del199/200 Gα11 mutant (Fig. 1E). However, 
despite the del199/200 mutant having an almost 
identical EC50 value to the Gln135 Gα11 mutant 
protein, these cinacalcet doses were insufficient to 
rectify the loss-of-function associated with the 
del199/200 Gα11 mutant (Fig. 1E). Subsequently, 
when cinacalcet was added at a 40 nM 
concentration to cells expressing the del199/200 
mutant, this lowered the EC50 value to 2.68 ± 0.04 
mM (Fig. 1E), so that the del199/200 mutant 
concentration-response curve overlapped with that 
of the WT Gα11 protein (Fig. 1G). 
Effect of NPS-2143 on the Ca2+i responses 
of ADH2-associated Gα11 mutations - We 
previously reported the germline Arg181Gln and 
Phe341Leu Gα11 mutations to enhance the 
sensitivity of CaSR-expressing cells to Ca2+o (1), 
thereby giving rise to the hypocalcemic disorder of 
ADH2. To determine whether allosteric inhibition 
of the CaSR can rectify the gain-of-function 
associated with ADH2-causing Gα11 mutations, 
WT or ADH2-associated mutant GNA11-pBI-
CMV2 vectors were transiently transfected into 
HEK-CaSR cells, and the responses of [Ca2+]i to 
alterations in [Ca2+]o assayed. Expression of the 
CaSR and Gα11 was demonstrated by fluorescence 
microscopy and/or Western blot analysis (Fig. 2A 
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and B). Western blot analysis confirmed an 
increase in the expression of Gα11 in cells 
transfected with WT or ADH2-associated mutant 
proteins, when compared to cells transfected with 
empty vector alone (Fig. 2B). An assessment of 
the Ca2+i responses of HEK-CaSR cells transiently 
transfected with WT or ADH2-associated mutant 
Gα11 proteins following stimulation with Ca2+o, 
demonstrated cells expressing the Gln181 or 
Leu341 mutants to induce a leftward shift of the 
concentration-response curves (Fig. 2C) with a 
significant increase in AUC values and reduction 
in EC50 values of 2.38 ± 0.08 and 2.29 ± 0.07 mM, 
respectively, compared to 2.57 ± 0.03 mM for WT 
expressing cells (p<0.0001) (Fig. 2D and E), as 
previously reported (1). The addition of NPS-2143 
to cells expressing the Gln181 Gα11 mutant 
revealed a 10 nM concentration of this calcilytic 
compound to normalize the mutant EC50 value to 
2.57 ± 0.07 mM (Fig. 2E), so that the 
concentration-response curve resembled that of 
WT Gα11 (Fig. 2F), whereas 20 nM NPS-2143 
significantly increased the mutant EC50 value to 
2.72 ± 0.12 mM when compared to WT expressing 
cells (Fig. 2E). In contrast to these studies 
involving the Gln181 Gα11 mutant protein, the 
addition of 20 nM NPS 2143 to cells expressing 
the Leu341 Gα11 mutant did not significantly alter 
the EC50. (Fig. 2E). Indeed, NPS-2143 at a 
concentration of 30 nM was required to decrease 
the Leu341 mutant EC50 value to 2.66 ± 0.09 mM 
and rectify the shift in the mutant concentration-
response curve (Fig. 2E and G). 
Effect of CaSR allosteric modulators on 
the Ca2+i responses in absence of endogenously 
expressed WT Gα11 protein - To determine whether 
CaSR-targeted drugs rectify the Ca2+i responses of 
FHH2- and ADH2-mutant expressing cells by 
directly influencing mutant Gα11-signaling or by 
indirect effects on WT Gα11 protein that is 
endogenously expressed in HEK293 cells, siRNA 
knockdown of endogenous WT Gα11 was 
undertaken in HEK-Gα11 cells stably expressing 
WT, FHH2-associated Gln135, or ADH2-
associated Gln181 mutant Gα11 proteins. Western 
blot analysis demonstrated that siRNA with a 
scrambled sequence did not alter endogenous WT 
Gα11 expression in untransfected HEK293 cells 
(Fig. 3A). In contrast, GNA11-targeted siRNA 
reduced endogenous WT Gα11 expression in 
untransfected HEK293 cells (Fig. 3A), and 
decreased the level of transiently expressed WT 
Gα11 in HEK293 cells (Fig. 3B), but did not affect 
the levels of stably expressed WT or mutant Gα11 
proteins in HEK-Gα11 cells (Fig. 3B), which 
contained constructs with silent mutations that had 
rendered them resistant to GNA11-targeted siRNA. 
CaSR constructs were transiently transfected into 
HEK-Gα11 cells, and CaSR expression confirmed 
by fluorescence microscopy (Fig. 3C). The effects 
of cinacalcet or NPS-2143 on the Ca2+i responses 
of the FHH2- and ADH2-associated Gα11 mutants 
were assessed following knockdown of 
endogenous WT Gα11 using GNA11-targeted 
siRNAs (Fig. 3D-G). These studies revealed that: 
10 nM of cinacalcet could rectify the rightward 
shift in the concentration-response curve and 
lower the significantly raised EC50 of the FHH2-
associated Gln135 Gα11 mutant from a value of 
3.85 ± 0.12 mM to values of 3.23 ± 0.1 mM and 
3.17 ± 0.08 mM, respectively, in the presence of 
GNA11-targeted or scrambled siRNA (Fig. 3D and 
E), so that these values were not significantly 
different from HEK-Gα11 cells stably expressing 
WT Gα11 (EC50 = 3.33 ± 0.06 mM); and that 10 
nM of NPS-2143 could normalize the leftward 
shift of the concentration-response curve and 
increased the EC50 of the ADH2-associated 
Gln181 Gα11 mutant from a value of 2.70 ± 0.07 
mM to values of 3.26 ± 0.06 mM and 3.11 ± 0.08 
mM, respectively, in the presence of GNA11-
targeted or scrambled siRNA (Fig. 3F and G), so 
that these values were not significantly different 
from WT-expressing HEK-Gα11 cells. Thus, these 
results show that CaSR-targeted drugs can 
influence the signaling responses of downstream 
mutant Gα11 proteins. 
 Effect of ADH2-associated Gα11 mutants 
on MAPK signaling - To investigate whether the 
germline Arg181Gln and Phe341Leu ADH2-
associated mutant Gα11 proteins may lead to 
constitutive upregulation of MAPK signaling, WT 
and mutant GNA11-pBI-CMV2 vectors were 
transiently transfected into HEK-CaSR cells and 
fold-change ERK phosphorylation (phospho-ERK) 
responses assessed following exposure to varying 
[Ca2+]o. The effects of the ADH2-associated 
mutants on phospho-ERK responses were 
compared to the uveal melanoma-associated 
Gln209Leu Gα11 mutation (11). Following 
stimulation with Ca2+o, the germline Gln181 and 
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Leu341 mutants were revealed to have 
significantly (p<0.001) increased maximal 
phospho-ERK fold-change responses (Gln181 = 
18.1 ± 1.1, Leu341 = 18.3 ± 0.9) compared to WT 
Gα11 (14.7 ± 0.3), consistent with a gain-of-
function (Fig. 4A). However, in the absence of 
Ca2+o stimulation, the basal phospho-ERK 
responses of the ADH2 mutants were 
demonstrated to not differ from WT Gα11 (Fig. 4A 
and B), and thus these mutants are not 
constitutively activating. In contrast, the tumor-
associated somatic Gln209Leu Gα11 mutation led 
to both significantly (p<0.0001) increased basal 
and maximal phospho-ERK fold-change responses 
when compared to the ADH2 mutants or WT 
Gα11, consistent with a constitutive upregulation of 
MAPK signaling (Fig. 4A and B). The effect of 
NPS-2143 on the phospho-ERK responses of 
HEK-CaSR cells expressing the ADH2-associated 
Gln181 or Leu341 mutants, or the uveal 
melanoma-associated Leu209 mutant, was also 
assessed. NPS-2143 was added at 10 and 30 nM 
concentrations to cells expressing the Gln181 and 
Leu341 mutants, respectively, as these doses had 
rectified the Ca2+i responses of the Gα11 mutants 
(Fig. 2F and G). The addition of 10 and 30 nM 
NPS-2143 significantly lowered the maximal fold-
change responses of the Gln181 and Leu341 
mutants to 14.0 ± 0.5 and 14.9 ± 0.4, respectively, 
so that these values did not differ from the 
phospho-ERK responses of cells expressing WT 
Gα11 (Fig. 4C and D). However, cells expressing 
the uveal melanoma-associated Leu209 mutant 
required NPS-2143 at a higher dose of 500 nM to 
successfully rectify increases in phospho-ERK 
responses (Fig. 4E). 
 
DISCUSSION 
Our studies demonstrate that cinacalcet 
and NPS-2143, which are allosteric CaSR 
activators and inactivators, respectively, can 
successfully rectify the loss-of-function associated 
with FHH2-causing Gα11 mutations and the gain-
of-function associated with Gα11 mutations that 
lead to ADH2 or uveal melanomas (1,11). 
Cinacalcet and NPS-2143 are allosteric 
modulators that are predicted to bind to the CaSR 
transmembrane domain (24) and influence 
receptor activity by altering its conformational 
status. These compounds have been reported to 
rectify the activity of FHH1- and ADH1-
associated mutant CaSR proteins in vitro (15,25-
27). However, the ability of these agents to 
normalise CaSR sensitivity in the presence of an 
abnormality downstream of the CaSR remained 
unknown. The in vitro findings of our study 
indicate allosteric modulation at the level of the 
receptor can rectify such loss- and gain-of-
function associated with mutations of the 
intracellular Gα11 protein. Indeed, these studies 
demonstrate that pharmacological GPCR 
modulation may directly overcome abnormalities 
affecting the downstream effector G-protein rather 
than by indirect effects on endogenously expressed 
WT G-proteins.  
However, the Gα11 mutations showed 
differences in their responsiveness to allosteric 
CaSR modulators. For example, our study of the 
FHH2 mutants revealed that a 4-fold increase in 
the cinacalcet dose was required to normalise the 
loss-of-function associated with Ile199/200del 
compared to the Leu135Gln mutation, despite both 
mutations having similar EC50 values. Similarly, a 
3-fold increase in the NPS-2143 dosage was 
required to rectify the gain-of-function due to the 
ADH2-associated Phe341Leu mutation when 
compared with the gain-of-function Arg181Gln 
mutation, despite both mutations having similar 
EC50 values. Thus, the Ile199/200del and 
Phe341Leu mutations showed diminished 
sensitivity to cinacalcet and NPS-2143, 
respectively, and these differences in the 
sensitivities of the mutants to CaSR-targeted drugs 
may be explained by a reported crystallography 
study, which showed residues homologous to 
Ile199 and Phe341, in the related Gαs protein to be 
located at the interface between GPCR and Gα-
subunit (28). Thus, Gα11 mutations located at the 
GPCR-Gα interface may potentially influence the 
efficacy of CaSR allosteric modulators.  
Cells expressing loss- and gain-of-
function Gα11 mutants responded to nanomolar 
concentrations of cinacalcet (10-40 nM, which is 
equivalent to 3.6-14.3 ng/mL) and NPS-2143 (10-
30 nM, which is equivalent to 4.4-13.3 ng/mL), 
respectively. However, previous in vitro studies of 
CaSR mutations leading to FHH and ADH have 
indicated that micromolar concentrations of these 
drugs may be required to rectify associated signal 
transduction abnormalities (25-27), and in vivo 
studies in WT rats have reported that the plasma 
drug concentrations of cinacalcet and NPS-2143 
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required to alter PTH secretion are ≥20 ng/mL and 
>100 ng/mL, respectively (29,30). The 
responsiveness of Gα11 mutants to low doses of 
CaSR-targeted drugs may be explained by the 
finding that these mutants induced only minor 
disturbances of CaSR signal transduction. Indeed, 
the FHH2 and ADH2 mutants were associated 
with up to a 30% shift in the EC50 values of HEK-
CaSR cells used in this study, whereas CaSR 
mutations leading to FHH1 and ADH1 generally 
cause a >50% shift in the EC50 value (9,21,31,32). 
However, it remains to be established whether 
such low concentrations of calcimimetic and 
calcilytic drugs will be able to rectify in vivo the 
alterations in mineral homeostasis in FHH2 and 
ADH2 patients.  
Somatic gain-of-function Gα11 mutations 
that induce constitutive MAPK activation have 
been reported in uveal melanoma and are 
associated with an increased likelihood of 
metastases (11). We therefore assessed the effects 
of germline ADH2-associated Arg181Gln and 
Phe341Leu gain-of-function Gα11 mutations on 
MAPK signaling by measuring phospho-ERK 
responses. Our studies demonstrated that the 
ADH2 Gα11 mutants induced a milder increase in 
ERK phosphorylation when compared to the uveal 
melanoma Gln209Leu Gα11 mutant. Moreover, up-
regulation of ERK phosphorylation by the ADH2-
associated Gα11 mutants only occurred in the 
presence of Ca2+o stimulation, and therefore these 
Arg181Gln and Phe341Leu Gα11 mutants do not 
harbor constitutive activity. These findings are 
consistent with a recent report of an ADH2-
associated Arg60Leu Gα11 mutation, which also 
enhanced MAPK activation in a non-constitutive 
manner (7). The finding that ADH2-associated 
mutations are not constitutively activating can be 
explained by their locations within the GTPase 
domain of the Gα subunit. Thus, the Gln209 
residue, which is mutated in uveal melanomas 
(11), is required to spatially orientate the terminal 
phosphate group of Gα-bound GTP (33), thereby 
facilitating its hydrolysis and the conversion of 
GTP to GDP. Mutations affecting the Gln209 
residue have been shown to abolish GTP 
hydrolysis, thereby leaving the Gα subunit in a 
permanent GTP-bound state of activation (34). In 
contrast, the Arg181 and Phe341 Gα11 residues, 
which are mutated in ADH2, are not located near 
to the terminal phosphate of GTP, and likely 
induce more indirect and subtle effects on GTP 
hydrolysis (1). The ADH2-associated Gα11 
mutations represent the first reports of non-
constitutively activating G-protein mutations 
(1,6,7), and the milder nature of these mutations is 
consistent with post-natal survival, in contrast to 
the constitutively activating Gln209Leu mutation, 
which has been shown to be cytotoxic when 
expressed at high levels (35), and is likely to be 
embryonically lethal. The occurrence of non-
constitutively activating Gα11 mutations that are 
tolerated in humans and heritable, highlights the 
potential for such germline mutations to affect 
other G-proteins and be associated with disease-
related phenotypes, and this possibility remains to 
be explored.  
In summary, our studies have revealed 
that germline gain-of-function Gα11 mutations 
induce non-constitutive alterations in MAPK 
signaling, and that CaSR-targeted compounds may 
rectify signaling disturbances caused by germline 
and somatic Gα11 mutations, which are associated 
with calcium disorders and tumorigenesis, 
respectively. These findings indicate that allosteric 
modulation at the level of the receptor may 
influence signaling disturbances associated with 
mutations of the downstream G-protein.  
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FIGURE LEGENDS 
 
FIGURE 1. Effect of cinacalcet on the Ca2+i responses of FHH2-associated Gα11 mutations. A. 
Fluorescence microscopy of HEK293 cells stably expressing CaSR (HEK-CaSR) and transiently 
transfected with WT or FHH2-associated (Gln135 and del199/200) mutant (m) GNA11-pBI-CMV2-GFP 
constructs, or with vector only. GFP expression in these cells indicates successful transfection and 
expression by these constructs. Bar indicates 20µm. B. Western blot analysis of whole cell lysates using 
antibodies to CaSR, α-tubulin and Gα11. Transient transfection of WT or FHH2-associated mutant 
constructs resulted in over-expression of Gα11 when normalised to α-tubulin expression. C-D. Ca2+i 
response to changes in [Ca2+]o of HEK-CaSR cells transfected with WT or FHH2-associated Gα11 
mutants. The Ca2+i responses to changes in [Ca2+]o are expressed as a percentage of the maximum 
normalized responses and shown as the mean ± SEM of 6-16 assays from 2-4 independent transfections. 
The FHH2-associated Gα11 mutants (Gln135 and del199/200) led to a rightwards shift of the 
concentration-response curves (blue) with significantly reduced AUC values when compared with WT 
Gα11 (black), which harbors Leu and Ile residues at codons 135 and 199/200, respectively. E. The FHH2-
associated Gln135 and del199/200 mutants (blue bars) are associated with significantly increased EC50 
values compared to cells expressing WT Gα11 (open bar). The addition of 10 and 20 nM cinacalcet (Cin) 
decreased the EC50s of cells expressing Gln135 to values that were not significantly different from WT, 
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whereas 40 nM cinacalcet was required to rectify the increased EC50 value of cells expressing the 
del199/200  mutant. F-G. The addition of cinacalcet at 10 and 40 nM concentrations rectified the 
rightward shift in the concentration-response curves of the Gln135 and del199/200 mutant Gα11 proteins, 
respectively. *p<0.05, ***p<0.0001. 
 
FIGURE 2. Effect of NPS-2143 on the Ca2+i responses of ADH2-associated Gα11 mutations. A. 
Fluorescence microscopy of HEK293 cells stably expressing CaSR (HEK-CaSR) and transiently 
transfected with vector, WT or ADH2-associated (Gln181 and Leu341) mutant (m) constructs. GFP 
expression in these cells indicates successful transfection and expression by these constructs. Bar 
indicates 20µm. B. Western blot analysis of whole cell lysates using antibodies to CaSR, α-tubulin and 
Gα11. Transient transfection of WT or ADH2-associated mutant constructs resulted in over-expression of 
Gα11 when normalised to α-tubulin expression. C-D. Ca2+i response to changes in [Ca2+]o of HEK-CaSR 
cells transfected with WT or ADH2-associated Gα11 mutants. The Ca2+i responses to changes in [Ca2+]o 
are expressed as a percentage of the maximum normalized responses and shown as the mean ± SEM of 6-
16 assays from 2-4 independent transfections. The ADH2-associated Gα11 mutants (Gln181 and Leu341) 
led to a leftwards shift of the concentration-response curves (red) with significantly increased AUC values 
when compared with WT Gα11 (black), which harbors Arg and Phe residues at codons 181 and 341, 
respectively. E. The ADH2-associated Gln181 and Leu341 mutants (red bars) are associated with 
significantly reduced EC50 values compared to cells expressing WT Gα11 (open bars). The addition of 10 
nM NPS-2143 (2143) increased the EC50 value of cells expressing Gln135 so that this was not 
significantly different from WT, whereas 30 nM of NPS-2143 was required to rectify the reduced EC50 
value of cells expressing the Leu341 mutant. F-G. The addition of NPS-2143 at 10 and 30 nM 
concentrations rectified the leftward shift in the concentration-response curves of the Gln181 and Leu341 
mutant Gα11 proteins, respectively. *p<0.05, **p<0.01, ***p<0.0001. 
 
FIGURE 3. Effect of cinacalcet and NPS-2143 on the Ca2+i responses of FHH2- and ADH2-
associated Gα11 mutations following siRNA knockdown of endogenously expressed WT Gα11.  A. 
Western blot analysis of untransfected HEK293 cells, which express endogenous WT Gα11 only, and have 
been treated with either scrambled siRNA, or three different GNA11-targeted siRNAs (siRNAs 1-3), 
either alone or all together (siRNAs 1+2+3), and compared to untreated HEK293 cells. All three GNA11-
targeted siRNAs, but not scrambled siRNA, reduced endogenous WT Gα11 expression. B. Western blot 
analysis showing combined effects of the three GNA11-targeted siRNAs on Gα11 protein expression in 
HEK293 cells transiently expressing WT Gα11 proteins and in HEK-Gα11 cells, which stably express WT 
or mutant Gα11 proteins. Use of GNA11-targeted siRNAs reduced Gα11 expression in HEK293 cells, but 
not in HEK-Gα11 cells, which are resistant to GNA11-targeted siRNA. C. Fluorescence microscopy 
confirming transfection of untreated and siRNA-treated (scrambled or combined siRNAs 1+2+3) HEK-
Gα11 cells with the pEGFP-CaSR construct. Bar indicates 50µm. D-E. Ca2+i response to changes in [Ca2+]o 
of FHH2-associated mutant Gln135 HEK-Gα11 cells following siRNA knockdown of endogenous WT 
Gα11. The Ca2+i responses to changes in [Ca2+]o are expressed as a percentage of the maximum normalized 
responses and shown as the mean ± SEM of 4-5 independent transfections (i.e. biological replicates). The 
FHH2-associated Gα11 mutant (Gln135) led to a rightward shift of the concentration-response curve 
(blue), with a significant increase in EC50 value compared to WT Gα11 (black). The addition of 10 nM 
cinacalcet (Cin) normalized the EC50 values of cells in the presence of scrambled (grey) or GNA11-
targeted siRNAs (siRNAs 1+2+3) (red). F-G. Ca2+i response to changes in [Ca2+]o of ADH2-associated 
mutant Gln181 HEK-Gα11 cells following siRNA knockdown of endogenous WT Gα11. The ADH2-
associated Gα11 mutant (Gln181) led to a leftward shift of the concentration-response curve (blue), with a 
significant decrease in EC50 value compared to WT Gα11 (black). The addition of 10 nM NPS-2143 
(2143) normalized the EC50 value of cells in the presence of scrambled (grey) or GNA11-targeted siRNAs 
(siRNAs 1+2+3) (red). ***p<0.0001; -, nil; scram, scrambled. 
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FIGURE 4. Phospho-ERK responses of Gα11 mutations associated with ADH2 or uveal melanoma. 
A. The phospho-ERK response to changes in [Ca2+]o was measured by quantitative immunoassay 
(Alphascreen) in HEK-CaSR cells transiently transfected with WT or ADH2-associated Gα11 mutants 
(Gln181 and Leu341), or the uveal melanoma (UV)-associated Leu209 Gα11 mutant protein. Phospho-
ERK responses at each [Ca2+]o are expressed as a fold-change of the response of cells stimulated with 
basal (0.5 mM) [Ca2+]o, and are shown as the mean ± SEM of 9-24 assays from 3-8 independent 
transfections. The uveal melanoma-associated Leu209 Gα11 mutant is associated with significantly 
increased maximal phospho-ERK fold-change responses compared to WT (Qln209) and the ADH2 
mutant Gα11 proteins. The Gln181 and Leu341 mutants also induce significant increases in maximal 
phospho-ERK fold-change responses compared to WT Gα11, which harbors Arg and Phe residues at 
codons 181 and 341, respectively. B. Quantification of the basal phospho-ERK responses shown in A. 
Values are expressed as a percentage of the WT basal phospho-ERK response. The uveal melanoma-
associated Leu209 Gα11 mutant induces a significant phospho-ERK elevation when exposed to basal 0.5 
mM [Ca2+]o, whereas the basal phospho-ERK responses of the ADH2-associated Gα11 mutants are not 
significantly different compared to WT Gα11. C-E. The addition of NPS-2143 (2143) at 10, 30 and 500 
nM concentrations significantly decreased the phospho-ERK responses of the ADH2-associated Gln181 
and Leu341 Gα11 mutants, and the UV-associated Leu209 mutant Gα11 protein, respectively, to values that 
were not significantly different from WT Gα11. ***p<0.0001. 
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